Synthesis and preliminary biological evaluation of potent and selective 2-(3-alkoxy-1-azetidinyl) quinolines as novel PDE10A inhibitors with improved solubility
摘要:
We report the discovery of a novel series of 2-(3-alkoxy-1-azetidinyl) quinolines as potent and selective PDE10A inhibitors. Structure-activity studies improved the solubility (pH 7.4) and maintained high PDE10A activity compared to initial lead compound 3, with select compounds demonstrating good oral bioavailability. X-ray crystallographic studies revealed two distinct binding modes to the catalytic site of the PDE10A enzyme. An ex vivo receptor occupancy assay in rats demonstrated that this series of compounds covered the target within the striatum. (C) 2014 Elsevier Ltd. All rights reserved.
Synthesis and preliminary biological evaluation of potent and selective 2-(3-alkoxy-1-azetidinyl) quinolines as novel PDE10A inhibitors with improved solubility
摘要:
We report the discovery of a novel series of 2-(3-alkoxy-1-azetidinyl) quinolines as potent and selective PDE10A inhibitors. Structure-activity studies improved the solubility (pH 7.4) and maintained high PDE10A activity compared to initial lead compound 3, with select compounds demonstrating good oral bioavailability. X-ray crystallographic studies revealed two distinct binding modes to the catalytic site of the PDE10A enzyme. An ex vivo receptor occupancy assay in rats demonstrated that this series of compounds covered the target within the striatum. (C) 2014 Elsevier Ltd. All rights reserved.
HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS
申请人:Amgen Inc.
公开号:US20130253186A1
公开(公告)日:2013-09-26
Heteroaryloxyheterocyclyl compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, Huntington's Disease, bipolar disorder, obsessive-compulsive disorder, and the like.
Synthesis and preliminary biological evaluation of potent and selective 2-(3-alkoxy-1-azetidinyl) quinolines as novel PDE10A inhibitors with improved solubility
作者:Robert M. Rzasa、Michael J. Frohn、Kristin L. Andrews、Samer Chmait、Ning Chen、Jeffrey G. Clarine、Carl Davis、Heather A. Eastwood、Daniel B. Horne、Essa Hu、Adrie D. Jones、Matthew R. Kaller、Roxanne K. Kunz、Silke Miller、Holger Monenschein、Thomas Nguyen、Alexander J. Pickrell、Amy Porter、Andreas Reichelt、Xiaoning Zhao、James J.S. Treanor、Jennifer R. Allen
DOI:10.1016/j.bmc.2014.10.013
日期:2014.12
We report the discovery of a novel series of 2-(3-alkoxy-1-azetidinyl) quinolines as potent and selective PDE10A inhibitors. Structure-activity studies improved the solubility (pH 7.4) and maintained high PDE10A activity compared to initial lead compound 3, with select compounds demonstrating good oral bioavailability. X-ray crystallographic studies revealed two distinct binding modes to the catalytic site of the PDE10A enzyme. An ex vivo receptor occupancy assay in rats demonstrated that this series of compounds covered the target within the striatum. (C) 2014 Elsevier Ltd. All rights reserved.